Contact us Demo our platform

Metabolon @

CRC Scientific Day 2025

Dates: September 25, 2025
Location: Paris, France
Event Website: CRC Scientific Day 2025 – Centre de recherche des Cordeliers

Join Metabolon at CRC Scientific Day 2025

Metabolon is attending the 2025 CRC Scientific Day, an annual scientific symposium hosted by the Centre de Recherche des Cordeliers in Paris that brings together students, post‑docs and early-career researchers as well as globally recognized keynote speakers Centre de recherche des Cordeliers. This event gathers leading experts in oncology, immunology and metabolism research to explore cutting‑edge scientific findings and translational advances.

You will find Virginie Lambert and Alessandro Busetti at Metabolon’s table exhibition. Come by to learn more about how metabolomics is accelerating discovery in cancer metabolism and unlocking actionable biological insights across immuno‑metabolism and biomarker discovery.

Key Themes at CRC Scientific Day 2025

CRC Scientific Day 2025 will showcase innovative research and emerging technologies across key focus areas such as:

  • Metabolism and Immunology
  • Environment, exposome, and genome
  • Therapeutic innovation and personalized medicine
  • Ethics, research, and society

Metabolomics is a unifying thread across immunology, environment, therapy, and ethics. It shapes immune cell behavior, tumor microenvironments, and responses to treatment. Connects environmental exposures with genetic predisposition, enabling personalized medicine. It also highlights health disparities, raising ethical considerations in precision health plays a pivotal role in many of these themes by uncovering metabolic signatures that reflect tumor‑immune dynamics and by identifying actionable biomarkers to better stratify patients and tailor interventions.

The Role of Metabolomics in Cancer, Immunology & Metabolism

Unlike genomics or proteomics, which infer functional potential, metabolomics captures the end products of cellular activity—giving real‑time insight into physiological and pathophysiological states including tumor metabolism, immune activation, and treatment response.

Uniquely, metabolomics sits at the intersection of genetics, lifestyle, the environment, and microbiome influence, reflecting the cumulative impact of these factors on individual health. It bridges the gap between genotype and phenotype, accelerating translational research and making immuno‑oncology and metabolism research more predictive, preventive, and effective.

Find out more:
– Why Metabolomics – Metabolon
– Why Metabolomics: Your Guide to Metabolomics – Metabolon

Featured Session: learn more about the impact of metabolomics in reshaping cancer therapy strategies

12:55 – 13:05 Alessandro Busetti (Metabolon) – “From Data to Discovery: Real-World Applications of Untargeted Metabolomics in Cancer”

Untargeted metabolomics offers a unique window into the biochemical underpinnings of health and disease, uncovering layers of insight beyond what is accessible through genomics or proteomics alone. This presentation will introduce Metabolon’s industry-leading platform and illustrate its value through two case studies in oncology. The first highlights how metabolomics enabled the identification of predictive biomarkers for therapeutic response, supporting patient stratification and precision medicine efforts. The second case examines how a specific genetic mutation conferred resistance to a chemotherapeutic agent in acute lymphoblastic leukemia (ALL), and how metabolomic profiling revealed the underlying metabolic mechanism, leading to a therapeutic opportunity. These examples demonstrate how a metabolomics-driven, multi-omics approach can unlock actionable insights and accelerate translational cancer research.

Why visiting Metabolon’s booth at CRC Scientific Day 2025

Why Metabolon? | Metabolon

With 25 years of expertise, over 4,000 publications, more than 15,000 completed projects, and the world’s largest curated metabolite reference library (5,400+ level 1 & 2 annotated metabolites), Metabolon is the global leader in metabolomics.

We use high‑resolution mass spectrometry, stringent quality controls, and deep biochemical annotation to accurately identify and quantify metabolites across diverse sample types.

Our Integrated Bioinformatics Platform enables combining omics such as genomics, transcriptomics, and proteomics in one unified environment—with advanced stats, ML models and interactive visualization—for seamless translational research collaboration.

Don’t stay behind – incorporate high-quality metabolomics analysis in your project. Book a meeting with Virginie and Alessandro by filling the form on this page!

In the meantime, feel free to browse some helpful cancer, immunology & exposome resources:

Meet Metabolon’s Team at CRC Scientific Day 2025

Virginie Lambert, Sales & Business Development Director, France & Belgium. With over 15 years of experience in the Biotechnology and Life Sciences industry, will be your point of contact at Metabolon in France and Belgium. She will assist you in finding the best solutions and advancing in metabolomics thanks to her expertise in various omics. Her knowledge of academic research and R&D in the industry, will give you access to high quality services that meet the standards of your R&D projects. Virginie is based in the Rouen region, Normandy.

Alessandro Busetti, PhD, Field Metabolomic Scientist– Dr Busetti spent 10 years conducting research in academia, both as a Research Fellow at QUB and as a Research Associate at the University of Glasgow. His research focused on the discovery of marine-derived bioactives for biomedical applications and understanding the role of microbiomes in regulating host health. In 2016 he transitioned into industry and joined 4D Pharma PLC where he worked as the Senior Team Leader of the “Discovery-Micro” Department. There, he defined and implemented screening strategies to identify candidate LBP strains for several disease areas ranging from autoimmune diseases, solid tumors, neurodegenerative diseases, and more.

Let’s connect in Paris and discuss how metabolomics can support your immuno‑metabolism and biomarker discovery goals – book a meeting with Virginie and Alessandro using the form on this page.

Learn More About the Event

Schedule a Meeting

Latest Resources

Access a wealth of valuable resources to deepen your understanding about metabolomics and the scientific advancements it has empowered.

✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.